KYMR•benzinga•
Kymera Therapeutics Initiates Dosing In BroADen Phase 1B Clinical Trial Evaluating KT-621, Potent Degrader Of STAT6, In Patients With Moderate To Severe Atopic Dermatitis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 22, 2025 by benzinga